[go: up one dir, main page]

AR052104A1 - Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa - Google Patents

Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa

Info

Publication number
AR052104A1
AR052104A1 ARP060100361A ARP060100361A AR052104A1 AR 052104 A1 AR052104 A1 AR 052104A1 AR P060100361 A ARP060100361 A AR P060100361A AR P060100361 A ARP060100361 A AR P060100361A AR 052104 A1 AR052104 A1 AR 052104A1
Authority
AR
Argentina
Prior art keywords
inhibitors
hmg
colesterilo
esteres
protein
Prior art date
Application number
ARP060100361A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR052104A1 publication Critical patent/AR052104A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Una forma de dosificacion que incluye un inhibidor de la proteína de transferencia de ésteres de colesterilo en una forma de solubilidad mejorada y un inhibidor de la HMG-CoA reductasa, en la que la forma de dosificacion proporciona liberacion inmediata del inhibidor de la HMG-CoA reductasa y liberacion controlada y liberacion inmediata del inhibidor de la proteína de transferencia de ésteres de colesterilo.
ARP060100361A 2005-02-03 2006-02-01 Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa AR052104A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65004805P 2005-02-03 2005-02-03
US73922005P 2005-11-22 2005-11-22

Publications (1)

Publication Number Publication Date
AR052104A1 true AR052104A1 (es) 2007-02-28

Family

ID=36123425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100361A AR052104A1 (es) 2005-02-03 2006-02-01 Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa

Country Status (7)

Country Link
US (1) US20080145427A1 (es)
EP (1) EP1845953A1 (es)
JP (1) JP2006213713A (es)
AR (1) AR052104A1 (es)
CA (1) CA2601762A1 (es)
TW (1) TW200638950A (es)
WO (1) WO2006082500A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006129167A1 (en) * 2005-05-31 2006-12-07 Pfizer Products Inc. PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS
US20070026073A1 (en) 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
CA2612989A1 (en) * 2006-05-08 2007-11-08 Mcneil-Ppc, Inc. Osmotic dosage form
US11116728B2 (en) * 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
EP2091519B1 (en) 2006-11-30 2015-06-24 Bend Research, Inc Multiparticulates of spray-coated drug and polymer on a meltable core
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US10189957B2 (en) 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
US8414958B2 (en) 2008-02-27 2013-04-09 Thommen Medical Ag Implant and method for the manufacture thereof
EP2348835A4 (en) * 2008-09-28 2014-01-22 Knc Ner Acquisition Sub Inc MIXES FROM MULTICOLOR CATECHOL COMPOUNDS
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
BR112012004372B1 (pt) * 2009-08-28 2020-06-02 Hercules Incorporated Composição de revestimento de filme a partir de compostos em pó sólido
EP2314286A1 (de) * 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
IN2012DE00826A (es) * 2012-03-21 2015-08-21 Ranbaxy Lab Ltd
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
CN104069502B (zh) * 2013-03-29 2018-02-16 北京罗诺强施医药技术研发中心有限公司 复合骨架材料及其药物组合物
US20160183563A1 (en) * 2013-07-30 2016-06-30 Benemilk Oy Feed for lactating ruminants
WO2015016827A1 (en) * 2013-07-30 2015-02-05 Benemilk Oy Dietary compositions for ruminants and containers for storing and dispensing same
EP3134070B1 (en) 2014-04-21 2020-09-23 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient
JP2019131472A (ja) * 2016-05-31 2019-08-08 興和株式会社 医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69324504T2 (de) * 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
DE60039802D1 (de) * 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
KR20030069983A (ko) * 2000-08-15 2003-08-27 화이자 프로덕츠 인코포레이티드 치료용 조합물
RU2004123637A (ru) * 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2005011634A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors

Also Published As

Publication number Publication date
CA2601762A1 (en) 2006-08-10
TW200638950A (en) 2006-11-16
EP1845953A1 (en) 2007-10-24
JP2006213713A (ja) 2006-08-17
US20080145427A1 (en) 2008-06-19
WO2006082500A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
AR045203A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa
AR052104A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa
DOP2019000185A (es) Una formulación sólida de dosificación farmacéutica
MX2009010284A (es) Inhibidores de la tirosina-cinasa de bruton.
UY31897A1 (es) Combinación de metotrexato con inhibidores dhodh
CR20120244A (es) Inhibidores de la tirosina quinasa de bruton
HUS2100022I1 (hu) HIV integráz inhibitor hatású policiklusos karbamoil-piridon származékok
CY2016041I1 (el) Αναστολεις κινασης τυροσινης bruton
PH12012501539B1 (en) Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
MX2014000518A (es) Inhibidores de la tirosina quinasa de bruton.
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
NO20081636L (no) FAP - inhibitorer
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
NO20064555L (no) HIV-integraseinhibitorer.
EA200900073A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
CL2011002569A1 (es) Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r.
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
CY1111768T1 (el) Νεος παραγοντας μειωσης τριγλυκεριδιου
CL2012001159A1 (es) Composicion que comprende un inhibidor de alfa-1-proteinasa (api), y como minimo, un aminoacido; kit que comprende dicha composicion que se utiliza como una composicion farmaceutica adecuada para administracion intravenosa.
CL2016000179A1 (es) Formulación de combinación que contiene metformina de liberación prolongada e inhibidor de la hmg-coa reductasa de liberación inmediata.
CY1114113T1 (el) Συνδυασμος ενος αναστολεα του κολπικου ρευματος if και ενος βητα-αναστολεα
CL2012000350A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl.

Legal Events

Date Code Title Description
FB Suspension of granting procedure